New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - hydrochlorothiazide 12.5mg; quinapril hydrochloride 10.832mg equivalent to 10 mg quinapril free base;   - film coated tablet - 12.5mg/10mg - active: hydrochlorothiazide 12.5mg quinapril hydrochloride 10.832mg equivalent to 10 mg quinapril free base   excipient: candelilla wax crospovidone heavy magnesium carbonate lactose monohydrate magnesium stearate opadry pink oy-s-6937 povidone

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - hydrochlorothiazide 12.5mg; quinapril hydrochloride 21.664mg equivalent to 20 mg quinapril free base.;   - film coated tablet - 12.5mg/20mg - active: hydrochlorothiazide 12.5mg quinapril hydrochloride 21.664mg equivalent to 20 mg quinapril free base.   excipient: candelilla wax crospovidone heavy magnesium carbonate lactose monohydrate magnesium stearate opadry pink oy-s-6937 povidone

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - rifabutin 150mg - capsule - 150 mg - active: rifabutin 150mg - mycobutin is indicated for infections caused by mycobacteria, such as m. tuberculosis, m. avium intracellulare complex (mac) and other atypical mycobacteria. in infections caused by mac and other atypical mycobacteria such as m. xenopi, mycobutin has been shown to be effective for the treatment of both disseminated and localised disease, also in immunocompromised hiv positive patients. mycobutin is also indicated for the prophylaxis of m. avium intracellulare complex (mac) infections in immunodepressed patients with cd4 counts lower than or equal to 100/ml. in the treatment of tubercular disease, mycobutin has been shown to be effective for the treatment of patients with chronic pulmonary tuberculosis, even if caused by multidrug-resistant m. tuberculosis strains. in accordance with the commonly accepted criteria for the treatment of mycobacterial infections, mycobutin therapy should always be given in combination with other antimycobacterial drugs not belonging to the family of rifamycins.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - tozinameran 0.1 mg/ml equivalent to 10 µg/0.2ml dose after dilution;  ;  ;  ;   - concentrate for injection - 0.1 mg/ml - active: tozinameran 0.1 mg/ml equivalent to 10 µg/0.2ml dose after dilution         excipient: 1,2-distearoyl-sn-glycero-3-phosphocholine alc-0159 alc-0315 cholesterol sucrose trometamol trometamol hydrochloride water for injection - active immunisation to prevent coronavirus disease 2019 (covid-19) caused by sars-cov-2, in children aged 5 to 11 years. the use of this vaccine should be in accordance with official recommendations.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - tozinameran 0.1 mg/ml equivalent to 3 µg/0.2ml dose after dilution;  ;  ;  ;   - concentrate for injection - 0.1 mg/ml - active: tozinameran 0.1 mg/ml equivalent to 3 µg/0.2ml dose after dilution         excipient: 1,2-distearoyl-sn-glycero-3-phosphocholine alc-0159 alc-0315 cholesterol sucrose trometamol trometamol hydrochloride water for injection - active immunisation to prevent coronavirus disease 2019 (covid-19) caused by sars-cov-2, in infants and children aged 6 months to 4 years. the use of this vaccine should be in accordance with official recommendations.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - antithymocyte immunoglobulin 50 mg/ml (equine) - concentrate for injection - 250 mg/5ml - active: antithymocyte immunoglobulin 50 mg/ml (equine) excipient: glycine hydrochloric acid sodium hydroxide water for injection - atgam is indicated for the management of allograft rejection, including delay of onset of first rejection episode, in patients who have undergone renal transplantation.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sirolimus 0.51mg;  ; sirolimus 0.5mg - coated tablet - 0.5 mg - active: sirolimus 0.51mg   excipient: calcium sulfate carnauba wax dl-alpha tocopheryl acetate ferrous oxide glyceryl mono-oleate iron oxide yellow lactose monohydrate macrogol 20000 macrogol 8000 magnesium stearate microcrystalline cellulose opacode red s-1-15095 poloxamer 188 povidone purified talc shellac titanium dioxide active: sirolimus 0.5mg excipient: calcium sulfate carnauba wax dl-alpha tocopheryl acetate ferrous oxide glyceryl mono-oleate iron oxide yellow lactose monohydrate macrogol 20000 macrogol 8000 magnesium stearate microcrystalline cellulose opacode red s-1-15095 poloxamer 188 povidone purified talc shellac sucrose titanium dioxide - rapamune is indicated for the prophylaxis of organ rejection in patients at mild to moderate immunological risk receiving renal transplants. therapeutic drug monitoring of sirolimus is required.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sirolimus 1mg;  ; sirolimus 1mg - coated tablet - 1 mg - active: sirolimus 1mg   excipient: calcium sulfate carnauba wax dl-alpha tocopheryl acetate glyceryl mono-oleate lactose monohydrate macrogol 20000 macrogol 8000 magnesium stearate microcrystalline cellulose opacode red s-1-15095 poloxamer 188 povidone purified talc shellac sucrose titanium dioxide active: sirolimus 1mg excipient: calcium sulfate carnauba wax dl-alpha tocopheryl acetate glyceryl mono-oleate lactose monohydrate macrogol 20000 macrogol 8000 magnesium stearate microcrystalline cellulose opacode red s-1-15095 poloxamer 188 povidone purified talc shellac sucrose titanium dioxide - rapamune is indicated for the prophylaxis of organ rejection in patients at mild to moderate immunological risk receiving renal transplants. therapeutic drug monitoring of sirolimus is required.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sirolimus 2mg;  ; sirolimus 2mg - coated tablet - 2 mg - active: sirolimus 2mg   excipient: calcium sulfate carnauba wax dl-alpha tocopheryl acetate ferrous oxide glyceryl mono-oleate iron oxide yellow lactose monohydrate macrogol 20000 macrogol 8000 magnesium stearate microcrystalline cellulose opacode red s-1-15095 poloxamer 188 povidone purified talc shellac sucrose titanium dioxide active: sirolimus 2mg excipient: calcium sulfate carnauba wax dl-alpha tocopheryl acetate glyceryl mono-oleate lactose monohydrate macrogol 20000 macrogol 8000 magnesium stearate microcrystalline cellulose opacode red s-1-15095 poloxamer 188 povidone purified talc shellac sucrose titanium dioxide - rapamune is indicated for the prophylaxis of organ rejection in patients at mild to moderate immunological risk receiving renal transplants. therapeutic drug monitoring of sirolimus is required.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sirolimus 1 mg/ml;   - oral solution - 1 mg/ml - active: sirolimus 1 mg/ml   excipient: phosal 50 pg polysorbate 80 - rapamune is indicated for the prophylaxis of organ rejection in patients at mild to moderate immunological risk receiving renal transplants. therapeutic drug monitoring of sirolimus is required.